ASCO GI 2024 | Sequencing therapies in hepatocellular carcinoma

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Korea, discusses the current understanding of sequencing therapies in hepatocellular carcinoma (HCC). He emphasizes the existing landscape, which primarily involves first-line immunotherapy-based combination therapies such as atezolizumab plus anti-PD-L1 and anti-VEGF antibodies. However, after progression on these first-line regimens, there is a lack of evidence supporting specific second-line treatments. Dr Yoo underscores the need for further research to determine the optimal therapies, particularly in the context of emerging drugs and the evolving standard of care. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.